A Phase 1b, Multicenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of CC-90011 Given in Combination With Cisplatin and Etoposide in First Line, Extensive Stage Subjects With Small Cell Lung Cancer
Latest Information Update: 28 Aug 2024
At a glance
- Drugs Pulrodemstat (Primary) ; Carboplatin; Cisplatin; Etoposide; Nivolumab
- Indications Small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors Celgene Corporation
Most Recent Events
- 26 Aug 2024 Status changed from active, no longer recruiting to completed.
- 19 Apr 2024 Planned End Date changed from 27 Feb 2024 to 26 Jun 2024.
- 19 Apr 2024 Planned primary completion date changed from 27 Feb 2024 to 26 Jun 2024.